Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Neurofibromatosis 1 1Neoplasm Metastasis 1Leukemia, Myelomonocytic, Juvenile 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Follicular 1

Interventions

Mycophenolic Acid 17fludarabine phosphate 16Cyclophosphamide 15Whole-Body Irradiation 10Tacrolimus 10Melphalan 10Peripheral Blood Stem Cell Transplantation 9Filgrastim 9Cyclosporine 9Busulfan 9Antilymphocyte Serum 8Granulocyte Colony-Stimulating Factor 7thymoglobulin 6Methotrexate 6Cord Blood Stem Cell Transplantation 5fludarabine 4Thiotepa 4Radiotherapy 4Methylprednisolone 4Etoposide 4Cytarabine 4Stem Cell Transplantation 3Rituximab 3Clofarabine 3Transplantation 2Sirolimus 2Methylprednisolone Hemisuccinate 2Methylprednisolone Acetate 2Etanercept 2Alemtuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Juvenile × omipalisib × Clear all
NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
10 enrolled 11 charts
CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡